Insulet Corporation $PODD Shares Sold by USA Financial Formulas

Key Points

• USA Financial Formulas has reduced its stake in Insulet Corporation by 34.5%, owning 2,805 shares worth $881,000 after selling 1,478 shares during the 2nd quarter.
• Insulet received positive upgrades from several analysts, with JPMorgan raising its price target to $415.00 and a consensus rating of "Moderate Buy" on the stock.
• Insulet Corporation reported a 32.9% year-over-year revenue increase in its latest quarterly earnings, achieving $649.10 million, alongside an earnings per share of $1.17, surpassing estimates.

USA Financial Formulas decreased its position in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 34.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,805 shares of the medical instruments supplier's stock after selling 1,478 shares during the period. USA Financial Formulas' holdings in Insulet were worth $881,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of PODD. Inspire Investing LLC grew its stake in Insulet by 299.5% during the 1st quarter. Inspire Investing LLC now owns 4,119 shares of the medical instruments supplier's stock worth $1,082,000 after buying an additional 3,088 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in shares of Insulet by 55.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 5,229 shares of the medical instruments supplier's stock valued at $1,376,000 after buying an additional 1,867 shares during the period. Goldman Sachs Group Inc. increased its stake in Insulet by 1.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 579,302 shares of the medical instruments supplier's stock valued at $152,130,000 after purchasing an additional 10,628 shares in the last quarter. Gradient Investments LLC purchased a new position in Insulet in the 2nd quarter valued at approximately $17,429,000. Finally, Vident Advisory LLC purchased a new position in Insulet in the 1st quarter valued at approximately $216,000.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on PODD shares. Royal Bank Of Canada raised their price target on shares of Insulet from $330.00 to $350.00 and gave the stock an "outperform" rating in a research note on Friday, August 8th. Morgan Stanley reissued an "overweight" rating on shares of Insulet in a research report on Thursday, August 7th. JPMorgan Chase & Co. boosted their price target on Insulet from $340.00 to $415.00 and gave the company an "overweight" rating in a research report on Friday, September 12th. Wall Street Zen upgraded Insulet from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Finally, Piper Sandler boosted their price objective on Insulet from $320.00 to $360.00 and gave the stock an "overweight" rating in a research note on Tuesday, September 16th. Sixteen research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $345.47.

Insider Activity at Insulet

In other Insulet news, SVP Prem Singh sold 687 shares of the company's stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the sale, the senior vice president owned 3,456 shares in the company, valued at $1,200,925.44. This represents a 16.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Laetitia Cousin sold 797 shares of the company's stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the sale, the senior vice president owned 3,890 shares in the company, valued at $1,356,870.90. The trade was a 17.00% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.39% of the company's stock.

Insulet Trading Down 0.9%

NASDAQ:PODD opened at $305.98 on Thursday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. Insulet Corporation has a one year low of $225.37 and a one year high of $353.50. The business's 50-day simple moving average is $320.45 and its 200 day simple moving average is $297.85. The stock has a market cap of $21.54 billion, a price-to-earnings ratio of 93.00, a price-to-earnings-growth ratio of 2.56 and a beta of 1.40.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.25. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The firm had revenue of $649.10 million for the quarter, compared to analysts' expectations of $612.31 million. During the same quarter in the prior year, the firm posted $0.55 earnings per share. Insulet's revenue for the quarter was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, sell-side analysts predict that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.